ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

3 years ago 407

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 SPX, +0.83% is up 16.1%.

Read Entire Article

ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Related

How To Stay Ahead of the Competition with Expert Guest Posts...

Mohamed El-Erian says ‘trifecta’ of dangers will haunt the U...

Adobe Stock Sinks as Fiscal 2022 Forecast Falls Short of Est...

Boeing Loses Qantas Business to Airbus. But There’s Good New...

Trending

Popular

WATCH: Neal Katyal Says That if Weisselberg Doesn’t Cooperat...

Akamai adds new capabilities and tools for developers

What We Learned About Amazon's Warehouse Workers

NY Got Close to Passing Single-Payer Healthcare–Then Special...

Biden to Nominate 5 More Judges